NCT04500873 (RPA-LF) is a clinical trial in Cutaneous Leishmaniasis (Diagnosis), sponsored by Centro Internacional de Entrenamiento e Investigaciones Médicas.

Who is sponsoring NCT04500873?

NCT04500873 is sponsored by Centro Internacional de Entrenamiento e Investigaciones Médicas.

What condition does NCT04500873 study?

NCT04500873 studies Cutaneous Leishmaniasis (Diagnosis).

Is NCT04500873 still recruiting?

NCT04500873 is currently completed. Last updated 5 August 2020.

Last reviewed 2020-08-05 · How we verify

NCT04500873: RPA-LF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Performance of RPA-LF for Cutaneous Leishmaniasis

Completed Last updated 5 August 2020

What this trial tests

trial in Cutaneous Leishmaniasis (Diagnosis) in 128 participants. Completed in 20 December 2019.

Timeline

1 February 2018

Primary endpoint
20 December 2019

20 December 2019

Quick facts

Lead sponsor	Centro Internacional de Entrenamiento e Investigaciones Médicas
Status	Completed
Study type	OBSERVATIONAL
Enrollment	128
Start date	1 February 2018
Primary completion	20 December 2019
Estimated completion	20 December 2019
Sites	1 location across Colombia

Conditions studied

Cutaneous Leishmaniasis (Diagnosis) — all drugs for Cutaneous Leishmaniasis (Diagnosis) →

Sponsor

Centro Internacional de Entrenamiento e Investigaciones Médicas

Who can join

2 and older, any sex, with Cutaneous Leishmaniasis (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CL is public health in the Americas, diagnostic confirmation is required to start treatment, however current diagnostic methods have several limitations and its access is limited. Technical requirements of conventional molecular diagnostics and costs preclude their routine use in primary care facilities in rural areas. A recently developed method of Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA, has shown high accuracy in detecting Leishmania Viannia spp. We evaluated the diagnostic performance of the RPA-LF test in a laboratory reference center and field scenario with community participation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Diagnostic performance of a Recombinant Polymerase Amplification Test-Lateral Flow (RPA-LF) for cutaneous leishmaniasis in an endemic setting of Colombia.
Cossio A, Jojoa J, Castro MDM, Castillo RM, et al · · 2021 · cited 16× · PMID 33909619 · DOI 10.1371/journal.pntd.0009291

Verify or expand the search:

Other Centro Internacional de Entrenamiento e Investigaciones Médicas trials

Trials by the same sponsor.

NCT05533736 — Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04500873 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centro Internacional de Entrenamiento e Investigaciones Médicas
Last refreshed: 5 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04500873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing